Barclays’s Medpace MEDP Stock Holding History

Barclays’s Portfolio MEDP Stock Details MEDP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-30,000	Closed	-$6.53M	–	5364
2021 Q4	$6.53M	Sell	30,000 -21,400	-42%	-$4.48M	﹤0.01%	1525
2021 Q3	$9.73M	Buy	+51,400	New	+$9.37M	﹤0.01%	1213

Other funds holding MEDP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Barclays's MEDP Position: Q1 2026 in Review

Barclays increased its Medpace (MEDP) stake by 109% in Q1 2026, buying an estimated $16.7M and bringing the position to 62,707 shares worth $30.1M. The position accounts for 0.01% of the portfolio, ranked #935.

Barclays first reported a position in MEDP in Q3 2016 and has held it in 39 quarters since. 729 funds tracked by Wall St. Rank hold MEDP as of Q1 2026.

Barclays held 62,707 shares of Medpace worth $30.1M as of Q1 2026.
Barclays bought 32,660 Medpace shares in Q1 2026, an estimated $16.7M.
Medpace made up 0.01% of Barclays's portfolio in Q1 2026, its #935 holding.
Barclays first reported a position in Medpace in Q3 2016 and has held it in 39 quarters since.
729 funds tracked by Wall St. Rank held Medpace as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.